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Invasive transitional cell carcinoma (TCC) of the urinary bladder is traditionally treated with radical cystectomy. This approach results
in great morbidity and lifestyle changes, and approximately half of the patients treated in this way will experience recurrent TCC
despite surgery. An alternative approach using selective bladder-preservation techniques incorporates transurethral resection of
bladder tumours, radiation therapy, and chemotherapy. Over the past 20 years, international experience has demonstrated that this
approach is feasible, safe, and well tolerated. Furthermore, the long-term outcomes of overall survival and disease-free survival
compare favourably with the outcomes from radical cystectomy. The most important predictor of response is stage, with significantly
higher long-term survival in patients with T2 disease. Another important positive predictor of complete response to therapy is the
ability of the urologic oncologist to remove all visible tumour through a transurethral approach prior to initiation of radiation therapy.
A negative predictive factor is the presence of hydronephrosis, and age and gender do not affect disease-free survival. The majority of
patients who enjoy long-term survival do so with an intact native bladder. Quality of life studies have demonstrated that the retained
bladder functions well in nearly all of these patients. Selective bladder preservation will not entirely take the place of radical
cystectomy, but should be offered as an important alternative to patients newly diagnosed with muscle-invasive TCC.
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Radical cystectomy has been the standard treatment for
muscle invasive transitional cell carcinoma (TCC) of the bladder.
Radical surgery results, historically, in a long-term survival rate
of only 40–60% (Pagano et al, 1991; Waehre et al, 1993). More
recent analysis of radical cystectomy at a single institution
demonstrated a disease-specific survival of 67% with a median
follow-up of 65 months, and long-term overall survival of
45% (Dalbagni et al, 2001). Another single-institution series
stratified patients by pathologic stage, and found a recurrence-free
survival of 89% in pathologic T2, node-negative tumours, 50% in
T4 node-negative tumours, and 35% in patients with node-positive
tumours (Stein et al, 2001). The negative impact that urinary
diversion has on lifestyle is part of the impetus for a search for
alternatives.
Cystoscopic tumour resection alone or radiation therapy alone
provide inferior outcomes to radical cystectomy, with only 20–
40% local control rates in muscle invasive TCC. However, an
accumulation of international experience over the past two
decades has established that trimodality bladder preservation
treatment is a legitimate alternative in selected cases of patients
with muscle-invasive TCC. The algorithm for this approach is
initial cystoscopic resection of as much bladder tumour as is safely
possible, followed by a combination of bladder irradiation with
concurrent radiosensitising chemotherapy, followed by adjuvant
chemotherapy. Active cystoscopic surveillance of the bladder is
maintained throughout the treatment period, and radical cystect-
omy is advised in the event of persistent invasive disease. Although
randomised studies comparing this approach to surgery have not
been performed, survival outcomes with selective bladder pre-
servation are comparable to outcomes from radical cystectomy in
comparable patients. This review will focus on studies of selective
bladder-preserving treatment of muscle-invasive TCC, as well as
on quality of life measures in patients who have undergone this
treatment.
INTERNATIONAL EXPERIENCE WITH SELECTIVE
BLADDER PRESERVATION
Selective bladder preservation for muscle-invasive TCC in North
America has occurred primarily under the auspices of the
Radiation Therapy Oncology Group (RTOG) and the National
Bladder Cancer Group. A series of six consecutive RTOG clinical
trials has been completed to date. The initial study RTOG 85-12
treated 42 patients with daily radiation therapy and concurrent
cisplatin, and reported greater than 50% 5-year survival (Tester
et al, 1993). The approach was feasible, well tolerated by patients,
and resulted in 42% long-term survival with an intact bladder.
Subsequent studies conducted by the RTOG have explored
numerous additional questions, including the addition of other
chemotherapy agents to cisplatin, including 5-fluorouracil (5FU)
and paclitaxel, the feasibility of outpatient treatment with this
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use of hyperfractionated radiation therapy, and others. These
studies will be further described below.
Concurrently, a number of European groups engaged in
pioneering efforts in bladder-preserving approaches to treatment.
The University of Paris treated 54 patients with transurethral
surgery, followed by concomitant radiation and chemotherapy
(Housset et al, 1993). In this study, 5FU was added to cisplatin, and
twice daily radiation was employed. Treatment was well tolerated,
and disease-free survival was 62% at 3 years.
The University of Erlangen reported on their 10-year experience
of 79 patients treated with transurethral bladder resection followed
by daily radiation with concurrent cisplatin (Dunst et al, 1994).
Results were similar to those of the RTOG and the University of
Paris, with 52% 5-year overall survival and 41% survival with
intact bladder. Their experience was expanded in a subsequent
report in which 162 patients were treated with either cisplatin or
carboplatin (Sauer et al, 1998). The overall 5-year survival was
55%, and 44% of total patients survived long term with an intact
bladder. Patients treated with carboplatin did not have as
favourable an outcome as those treated with cisplatin, although
the numbers in each group were too small for meaningful
statistical comparison. A subsequent study demonstrated that the
combination of cisplatin and 5FU for radiosensitising chemo-
therapy was safe, tolerable, and efficacious (Rodel et al, 2002b).
A common theme among these studies was the use of salvage
radical cystectomy when necessary. Surveillance cystoscopy was
performed following combination treatment in the European
studies, whereas the RTOG and Massachusetts General Hospital
(MGH) studies employed an interval cystoscopy after an ‘induc-
tion’ period of treatment to assess the response. Patients with less
than complete response to combination therapy were referred for
radical cystectomy. The complete response rate found at cysto-
scopy following induction or completed therapy in these studies
was generally in the range of 65–75%. Patients with only
carcinoma in situ, or with superficial cancer at a new site, were
included in the group of complete responders, whereas patients
with any muscle-invasive bladder cancer, or with superficial cancer
at the original site, were referred for surgery.
In the largest series yet reported, the University of Erlangen
recently compiled their data on 415 patients treated with selective
bladder preservation over an 18-year period, including the 162
patients described in their prior study (Rodel et al, 2002a). Of the
415 patients, 89 had stage T1 disease only, and the remainder had
T2–T4. The large majority had no evidence of lymph node
metastases. Over 100 patients were treated with radiation alone,
whereas 289 were treated with concurrent chemotherapy and
radiation. Radiosensitising chemotherapy consisted of cisplatin
(145), carboplatin (95), or cisplatin and 5FU (49). Results were
reported for all 415 patients as a group, which somewhat obscured
the results for patients treated with combination therapy. The
complete response rate at interval cystoscopy was significantly
higher among patients treated with combination therapy than
among patients treated with radiation alone (P¼0.001). The
overall 5-year survival including T1 patients was 51%, and survival
with an intact bladder was 42%. The authors also found that initial
tumour response was a strong prognostic factor for disease-
specific survival and overall survival.
It is important to emphasise the role of transurethral debulking
(TURB) in combined modality bladder-preservation treatment.
The complete response rate of 65–75% at interval cystoscopy
reflects not only the effect of concurrent radiation and chemother-
apy, but also the effect of TURB. It is likely that TURB alone would
result in a complete response in some patients, and, even in those
with persistent microscopic disease after resection, the debulking
effect of TURB probably enhances the efficacy of concurrent
radiation and chemotherapy. Ability to completely resect visible
tumour was a strong predictor of complete response as well as
overall survival in univariate and multivariate analyses (Shipley
et al, 1987; Rodel et al, 2002a).
Another critical surgical point is the essential role of salvage
cystectomy in incomplete responders to combined modality
therapy. Of 190 patients treated with selective bladder preserva-
tion, 66 patients (35%) ultimately underwent radical cystectomy
for incomplete response to therapy or recurrent invasive
tumour (Shipley et al, 2002). The 5-year disease-specific
survival rate for these patients was 57% for stage T2 and 42%
for stage T3–T4a, confirming that salvage surgery is potentially
curative therapy for many patients in this program. Importantly,
no patients have required cystectomy to treat radiation-induced
bladder toxicity.
RTOG STUDIES
Since the initial publication of RTOG 85-12, this group has
completed a series of clinical trials examining combined modality
therapy (Table 1). A major effort was undertaken to determine the
role of neoadjuvant chemotherapy in studies 88-02 and, in a
randomised phase III trial, in 89-03 (Tester et al, 1996; Shipley et al,
1998). The majority of patients who relapse following definitive
local therapy have distant, rather than local, relapse, indicating the
likelihood of microscopic metastatic disease at the time of local
therapy. Thus, the use of systemic chemotherapy is employed in an
attempt to eradicate such microscopic disease. However, in 89-03,
treating patients with two cycles of MCV chemotherapy (metho-
trexate, cisplatin, vinblastine) prior to combination therapy failed
to improve survival or local tumour eradication. At a median
follow-up of 5 years, the overall survival was 48% in patients
treated with MCV, and 49% in the untreated arm. Cystoscopic
complete response was 61% in the MCV arm, and 55% in the
control arm. At 5 years, distant metastases were present in 35% of
the patients treated with neoadjuvant MCV, and 43% of
the untreated patients. None of these differences approached
statistical significance. Moreover, because of toxicity, the protocol-
completion rate for the MCV arm was only 67%. As a result,
some subsequent studies employed adjuvant rather than neoadju-
vant chemotherapy. Numerous randomised trials have explored





chemotherapy # of patients
5-year
survival Reference
85–12 None Daily Cisplatin 42 52% (Tester et al, 1993)
88–02 Neoadjuvant MCV Daily Cisplatin 91 62% (Tester et al, 1996)
89–03 +Neoadjuvant MCV Daily Cisplatin 123 49% (Shipley et al, 1998)
95–06 None Hypofractionated Cisplatin+5FU 34 N/A (Kaufman et al, 2000)
97–06 Adjuvant MCV Twice daily Cisplatin 52 N/A (Hagan et al, 2003)
99–06 Adjuvant GC Twice daily Cisplatin+paclitaxel 84 N/A —
MCV – methotrexate, cisplatin, vinblastine; 5FU – 5-fluorouracil; GC – gemcitabine, cisplatin; N/A – not available.
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radical cystectomy, a topic beyond the scope of this review
(Bajorin, 2001; Raghavan et al, 2002; Sternberg, 2002; Grossman
et al, 2003).
In subsequent RTOG studies, a number of modifications were
made to the radiation treatment. High-dose hypofractionation was
employed in 95-06, together with both cisplatin and 5FU for
radiosensitisation (Kaufman et al, 2000). Seven of 34 patients
(21%) experienced grade 3 or 4 haematological toxicity, though no
deaths resulted. No patients required cystectomy for radiation
toxicity, despite the high-dose hypofractionation. Complete
response was seen in 67% of patients, and 3-year overall survival
was 66%. The RTOG then turned to conventional twice-daily
hyperfractionation in 97-06 and subsequent studies. In 97-06, a
total of 45.6Gy was delivered to the pelvis and bladder, and 64.8Gy
to the bladder tumour. Individual fractions were 1.8Gy to the
pelvis with a boost of 1.6Gy to the bladder tumour during
induction treatment, twice a day for 12 days, and then 1.5Gy
fractions to both during consolidation treatment, twice a day for 8
days (Hagan et al, 2003). In 99-06, radiation was delivered in a
similar fashion with a boost to the whole bladder, and an
additional boost to the bladder tumour. The full results of these
studies are not yet published.
Initial RTOG studies required hospitalisation of patients to
deliver the combined modality treatment. However, since 95-06, all
treatments have been administered in the outpatient clinics, with
only rare hospitalisations for complications of therapy. This
approach has been feasible and safe, and has greatly increased the
appeal of combined modality therapy.
PREDICTORS OF OUTCOME
Initial clinical stage continues to be the most important predictor
of overall survival in patients treated for muscle-invasive bladder
cancer. In a series of 190 patients treated with selective bladder
preservation at the MGH, 5-year overall survival and disease-
specific survival were 62 and 63%, respectively, for stage T2, and
47 and 53% for stage T3–T4a (Shipley et al, 2002). Similarly, stage
was an important predictor of survival with an intact bladder. The
5-year disease-specific survival with an intact bladder was 57% for
patients with stage T2, but only 35% for patients with stage T3–
T4a. In the series from the University of Erlangen, 5-year overall
survival was 75% for stage T1, 56% for T2, 44% for T3, and 17% for
T4 (Rodel et al, 2002b).
The presence or absence of hydronephrosis at the time of
diagnosis has also affected treatment success. Of the 190 patients
reviewed at the MGH, 27 had initial hydronephrosis (Shipley et al,
2002). Their likelihood of complete response at the first interval
cystoscopy was 37%, compared with 68% in patients without
hydronephrosis (P¼0.002). Ultimately, 60% of these patients
underwent radical cystectomy, compared with 31% of the other
patients (P¼0.004). Despite the low total numbers of patients with
hydronephrosis, this factor approached statistical significance for
predicting survival in multivariate analysis. The 5-year overall and
disease-specific survivals were 48 and 53% for patients with
hydronephrosis, compared with 55 and 64% for patients without
hydronephrosis. As a result of this finding, patients with initial
hydronephrosis are generally excluded from bladder-preservation
protocols.
The initial response to treatment does not predict survival
outcome, but is an independent predictor of successful bladder
preservation. Not surprisingly, advanced age predicts poorer
overall survival for patients treated with selective bladder
preservation (Rodel et al, 2002b; Shipley et al, 2002). However,
there is no clear effect on disease-specific survival, suggesting that
age may not impact on the success of this treatment approach.
Gender has not been found to affect outcome.
COMPARISON WITH TREATMENT OUTCOMES FROM
CONTEMPORARY CYSTECTOMY SERIES
The discrepancy between clinical staging and pathologic staging is
an important confounding factor in comparing results of radical
cystectomy with results of bladder preservation. Since clinical
staging is more likely to understage the extent of disease, there is
an outcome bias in favour of surgical series that benefit from
pathologic staging. Nevertheless, outcomes from bladder preserva-
tion treatment compare favourably to outcomes reported from
contemporary surgical series.
Two large, single-institution surgical series have been recently
published. The University of Southern California reported on 1054
patients undergoing radical cystectomy (Stein et al, 2001). Of
these, 633 patients had pathologic stage T2–T4a, and their 5-year
overall survival rate was 48%. A second series, from Memorial
Sloan Kettering Cancer Center, reported a 5-year overall survival
rate of 36% in patients with T2–T4 tumours (Dalbagni et al, 2001).
Finally, a recent Intergroup study examining neoadjuvant che-
motherapy in patients undergoing radical cystecomy for muscle-
invasive bladder cancer reported a 5-year overall survival of 50%
(Grossman et al, 2003). In patients who underwent cystectomy
without receiving chemotherapy, the 5-year survival was only 43%.
Thus, even contemporary surgical series demonstrate a high rate of
disease recurrence for muscle-invasive disease, with cure rates no
higher than those that have been observed in current selective
bladder-preserving approaches (see Table 1). Comparison is
hindered by the lack of a phase III, randomised trial of the two
approaches. Unfortunately, cooperation for such an endeavour has
not yet been forthcoming from the different involved disciplines.
QUALITY OF LIFE OUTCOMES
There are legitimate concerns among physicians regarding the
long-term effects of high-dose bladder radiation on bladder
function, as well as the potential harmful effects to the bowel
and to erectile function in men. In earlier cross-sectional studies
from Italy and Sweden, over 74% of patients reported good long-
term urinary function, and low levels of patient-reported systems
(Caffo et al, 1996; Henningsohn et al, 2002). A recent study from
the MGH has studied the quality of life and urodynamics in a
comprehensive fashion among 49 patients who had completed
bladder preservation therapy a median of 6.3 years earlier
(Zietman et al, 2003). In all, 32 patients agreed to undergo formal
urodynamic evaluation. Of these, 24 were judged to have bladders
with normal function. The median volume voided was 284cm
3
(range 125–630cm
3), and median bladder capacity was 400cm
3
(range 221–747). Five of the 18 men studied had evidence of
reduced flow. Three had post-void residual of greater than 100cm
3,
and two of these had urodynamic evidence of bladder outlet
obstruction. Thus, impaired urinary function may have been due
to external factors and not to impaired bladder function per se.
One-fifth of all patients in the study reported some degree of
incontinence within the preceding week, and women were twice as
likely as men to report incontinence. Mild to moderate bowel
symptoms were reported by 20% of men and 27% of women. The
symptom most frequently reported was rectal urgency. A total of
14% reported moderate or greater symptoms, but no patients
reported severe or very frequent bowel symptoms. In two prior
studies, 10 and 32% of patients complained of moderate or greater
bowel symptoms. Sexual function among men was remarkably
intact, with 8% reporting dissatisfaction with their sex life, 33%
reporting neither satisfaction nor dissatisfaction, and 59% report-
ing satisfaction (Zietman et al, 2003). Sildenafil was used by 16% of
men, perhaps accounting in part for the favourable numbers
compared to earlier studies, in which only 25–40% of men
retained adequate sexual function (Caffo et al, 1996; Henningsohn
et al, 2002). The numbers in this study compare favourably to
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available for sexual function among women in this study.
The major conclusions of this recent study from the MGH were
that normal bladder function was preserved in the majority of
patients with an intact bladder years after bladder preservation
therapy, that about one-fifth of patients complained of mild to
moderate bowel symptoms, and that one-fifth of patients suffered
from occasional urinary incontinence.
CONCLUSIONS
The use of bladder-preservation therapy for muscle-invasive
TCC of the bladder is a valid alternative to radical cystectomy
in selected cases. Long-term efficacy is comparable to radical
cystectomy, with the advantage of preserving excellent
bladder function in the majority of long-term survivors.
Contemporary protocols utilise a combination of transurethral
tumour resection, concurrent radiation and radiosensitising
chemotherapy, and often adjuvant chemotherapy. These ap-
proaches require close coordination among surgical, radiation,
and medical oncologists. Treatments are well tolerated, and
are carried out in the outpatient setting. Future investigation will
optimise the use of systemic therapy during selective bladder
preservation, and will explore the role for rationally targeted
biologic agents in the management of locally advanced bladder
cancer.
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